MYBL2 and cancer: Differential gene expression analysis in the overall tislelizumab-treated GEA cohort identified genes highly expressed in TAP ≥ 5%, HA + tumors, including genes with functions in cell cycle regulatory (such as aurora kinase A [AURKA], ubiquitin-conjugating enzyme 2C [UBE2C], CDC20 and MYBL2), DNA repair (such as RAD54L and FANCD2), and hedgehog signaling (such as WNT5A and IHH) pathways, or with functions as cancer antigens (Supplementary Fig. 9).